香港，2025年6月13日 - (亚太商讯 via SeaPRwire.com) - 达丰设备服务有限公司（"达丰"或"公司"，连同其附属公司统称"集团"）（股份代号：2153）为在中国成立的首家外资塔式起重机服务供应商，公布其截至2025年3月31日止年度（"2025财年"或"年内"）的全年业绩。2025财年，集团的收益为人民币634.6百万元（2024财年：682.3百万元）。公司权益持有人应占亏损为人民币120.5百万元（2024财年：95.6百万元）。亏损增加主要是由于于(i)经济增长放缓及建筑业不景气导致收入下降；及(ii)递延税项调整导致所得税开支增加。截至 2025 年 3 月 31 日，集团全年平均管理的塔式起重机总数为1,180台。集团的使用总吨米由截至2024年3月31日止年度的3,178,404减少至截至2025年3月31日止年度的3,137,910。于2025年3月31日，集团有256个在建项目，未完成合同总价值约为人民币721.4百万元，手头项目共有38个，预计合同总价值约为人民币78.7百万元。于本财政年度内，在市场需求不足及塔式起重机每吨米平均每月服务价格下降的影响下，供需失衡导致整个工程机械行业面临激烈的市场竞争。为应付市场疲弱情况，集团因时制定不同战略，并不断地调整业务占比，逐年降低房地产行业的收入占比。集团积极回应国家提出的大力发展清洁能源的号召，并应市场发展趋势及发展潜力，专注于火电项目和核电项目。而清洁能源项目施工期长，规模大，集团依靠丰富的行业经验，成熟的施工技巧以及雄厚的技术实力取得相当的优势。于2025财年，集团加快推进境外市场的布局，通过大湾区和印尼深入贯彻集团运营策略，逐步扩大大中型塔式起重机机队。截止目前，香港和印尼的项目多半为大吨米塔机。由于以上原因，清洁能源和境外项目依旧是集团未来的发展重点。年内，集团继续投资于数字化管理平台及新的塔式起重机技术解决方案的研发。于2025年3月31日，集团拥有187项塔式起重机相关的实用新型及发明注册专利。雄厚的技术实力将继续助力集团获得项目，而在塔式起重机技术解决方案方面的研发能力提升将增强集团交付卓越服务的能力。达丰设备服务有限公司行政总裁邱国燊先生表示："除了房地产市场和建筑行业的低迷外，地缘政治紧张局势和人民币贬值压力进一步削弱了中国经济。为应对这些经济挑战和瞬息万变的营商环境，我们迅速调整了发展战略，包括拓展清洁能源建筑领域，并将地域范围扩展至大湾区及印尼。我们相信，这些举措的积极影响将在未来几年逐步显现。"达丰设备服务有限公司主席黄山忠先生总结："即使身处最艰难的环境，我们始终坚守初心。秉承'厚德、安全、卓越'的核心价值观，我们将在业务发展中持续追求卓越。在下一财年中，我们将进一步巩固在清洁能源及新市场的优势地位，把握市场新机遇，同时专注于塔式起重机新技术的研发，使我们具备最强大的技术能力，为客户提供卓越的服务。此外，我们还将持续推进资源共享及降本增效等举措。透过上述措施，我们相信，我们能够实现集团的企业愿景'做最好的建筑设备服务供应'。" Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年6月13日 - (亚太商讯 via SeaPRwire.com) - 随着国家「新质生产力」成为推动高质量发展的重要策略，义合控股有限公司（「义合控股」；香港主板上市编号：1662）旗下附属公司 Absolute Pure EnviroSci Limited（「APEL」或「本公司」）积极响应国家政策，携手香港生产力促进局（「生产力局」）共同建设智能微工厂，在香港实现Wisepura Aquapura多孔结构硅微囊专利技术产业化，推动香港智能制造和新型工业化。今年 3 月开幕的生产力局「生命健康科技馆」展示了逾 20 项由生产力局、InnoHK研发平台、本地大学及业界携手研发的科技成果及创新应用，包括Wisepura Aquapura多孔结构硅微囊专利技术。全球首个Wisepura Aquapura智能微工厂全面投入生产运营作为双方合作的重要成果，APEL 与生产力局合作建设的全球首个Wisepura Aquapura智能微工厂于 2025 年 6 月 13 日香港九龙湾正式启用，标志着「工业 4.0」的第一阶段正式落地和 APEL 科研成果产业化发展的重要里程碑。在投资界和商界众多嘉宾的见证下，义合控股主席詹燕群先生、APEL 主席钟伟强博士及 APEL 董事杨学光博士于启用典礼上共同为 APEL Wisepura Aquapura智能微工厂揭幕，正式宣告其投入生产运营。APEL 董事杨学光博士（左一）、义合控股主席詹燕群先生（左二）、生产力局总裁毕坚文先生（右二）及APEL 主席钟伟强博士（右一）于Wisepura Aquapura智能微工厂启用典礼合照。APEL 主席钟伟强博士表示：「我们非常荣幸可以与生产力局合作建设Wisepura Aquapura智能微工厂，并衷心感谢生产力局对 APEL 的支持，充分印证了我们在生命健康科技领域深厚的科研实力与创新能力。APEL Wisepura Aquapura智能微工厂的正式投产，提升了我们应对市场日益增长需求的能力，为公司发展注入新动能。展望未来，我们将持续拓展合作伙伴网络，积极拓展国际版图，致力将本地科研成果推向全球，为全球健康与环境保护贡献力量，携手共创可持续发展的美好未来。」APEL 主席钟伟强博士于启用典礼致辞。与山湖集团建立战略合作关系，共拓大湾区水质净化及水产养殖科技新机遇广东山湖集团有限公司（「山湖集团」）作为全球领先的室内空气环境处理专家，其核心产品大厦扇畅销全球六大洲，服务超过5,000万用户。十年前，山湖集团旗下公司山湖机电前胆性地投入研发智能节能养殖机械科技。2025年6月13日，APEL与山湖集团正式签署战略合作备忘录，共同进军水质净化治理及智能水产养殖领域。双方计划开发对水质净化设备、生态修复技术、智能监测系统等有较大需求的包括各类环保工程项目，如河道治理、黑臭水体整治、生态修复等环保工程市场。对新型过滤材料、水处理工艺、水质监测技术等有稳定需求包括城市污水处理厂、工业园区污水处理设施的市政污水处理市场。与政府环保部门、市政工程公司建立合作关系，参与污水处理项目的招投标，提供定制化解决方案。合作内容涵盖技术研发、市场拓展及资源共享。双方将联合开发智能水质监测系统，利用大数据及人工智能优化养殖决策，并针对环保工程、市政污水处理等市场推广高效净化技术。合作项目将深度融合山湖集团在机电设备与消毒技术的产业优势，以及APEL旗下Wisepura Aquapura智能微工厂的先进水处理专利技术。此合作为期一年，期满后可自动续约，通过双方商业及技术资源技术交流会，合作成果将率先在粤港澳大湾区推广应用，有望推动大湾区环保与水产养殖产业升级，带动产业链的升级转型，展望未来将逐步拓展至海外市场。APEL（左）与山湖集团签署战略合作备忘录。迈向「工业4.0」智能制造新时代在推动「工业 4.0」的进程上，APEL Wisepura Aquapura智能微工厂将人工智能、物联网、大数据等先进技术整合到制造流程，实现智能监控与自动化管理，提升整体运营效率与产品品质。为解决混合过程中温度急升对智能硅微囊结构和性能的影响，工厂安装了一套由物理人工智能（Physical AI）驱动的定制智能温控系统、工厂更配备人机介面（HMI）、可程式设计逻辑控制器（PLC）及在位清洗（CIP）系统，以提升生产效率与灵活性。此外，工厂引入工业物联网（IIoT）监控系统，实时监测用电情况，有效优化能源管理；同时透过及时化生产管理（JIT）有效减少仓库积压及资源浪费，全面推动智能制造的高效运营。一众嘉宾参观 APEL Wisepura Aquapura智能微工厂。健康与环境科技创新双重升级水资源是维系人类生命与生态环境健康的关键，但随着城市发展，水污染问题日益严重，对公共卫生和生态系统构成重大威胁。为改善水质，APEL 研发的Wisepura Aquapura采用了全球首创、并于 2022 年及 2024 年荣获日内瓦国际发明展一金一银奖项的多孔结构硅微囊专利技术。该技术能在与水接触时智能控释其活性物质，有效消灭逾 95%的有害微生物及耐药性细菌，同时满足多样化的应用需求。这项创新技术已广泛应用于香港多个公共基础设施，有效针对供水系统、空调系统及下水道系统中超过 30 种细菌、真菌及病毒，包括退伍军人症、手足口病原体、流感病毒及白色念珠菌等，显著减低水系统及气溶胶传播疾病的风险。此外，硅微囊系统可多次循环使用，且在使用寿命结束后亦能安全弃置，降低环境负担，为水质处理解决方案树立新标准。通过精益管理及智能制造的概念，APEL 全球首个Wisepura Aquapura智能微工厂在有限的空间内成功整合了定制的生产技术、机械自动化和数据可视化，实现灵活小批量定制生产和「工业 4.0 的 1i 成熟度水准」，为 Physical AI 的应用铺平了道路。APEL 全球首个Wisepura Aquapura智能微工厂成功整合了定制的生产技术、机械自动化及数据可视化，实现了「工业 4.0的 1i 成熟度水准」。关于APEL Wisepura Aquapura智能微工厂位于九龙湾的 APEL Wisepura Aquapura智能微工厂将实验室规模的工艺放大至中试规模，并巧妙适应香港传统多层工业建筑的空间限制，成功实现每日6吨的高效产能。生产线的核心在于其 C 形布局设计，为高效运作奠定基础。工厂配备混合系统、灌装及旋盖系统，以及智能化设置，并透过定制的管道系统连接 5 个药用级混合罐，实现全流程精益管理。针对有限空间，工厂特别配备了一台 2.5米高的自动上盖机，充分利用立面空间，展现空间利用与智能化的完美结合。智能微工厂的启用和投产，不仅大幅提升了生产效率，也加速了 APEL 与力霸水泵机械工程有限公司的合作进程，促进科研产品的市场拓展。此外，智能微工厂已获渠务署正式订单，彰显其解决方案获得高度认可，并为公司持续带来实质经济效益。为布局日本这个高度重视个人健康与环境卫生的市场，APEL 现正于大阪 The Lab.举行创新互动展览会，展示三大旗舰产品 - Wisepura水质及空气净化系统、GERMAGICTM抗菌涂层和 GERMAGICTM PET 宠物健康及护理方案，把握亚洲健康科技产业的发展机遇。关于义合控股有限公司义合控股有限公司为香港主板上市公司（1662.HK），是香港一间历史悠久的承建商，主要从事提供地基工程及隧道工程业务。此外，旗下联营公司 Windmill Street Development 于英国伯明罕发展优质物业项目。集团于 2023 年成立 Absolute Pure EnviroSci Limited （「APEL」），主要从事健康及环境创新业务，包括特种生化及生物医药产品之分销及研发业务，并先后与香港科技大学及香港科学园成立实验室。其中「香港科技大学-AP EnviroSci Ltd.环境科学健康与环境创新联合实验室」之联合实验室于 2024 年 1 月 10 日启用，而位于香港科学园之「APEL生物医药科技创新及转化商业实验室」亦于 2024 年 3 月 13 日正式启用。欲知更多有关义合控股有限公司资料，请浏览网页：http://www.yee-hop.com.hk/关于 Absolute Pure EnviroSci LimitedAbsolute Pure EnviroSci Limited（「APEL」）为香港联合交易所主板上市公司-义合控股有限公司（香港主板上市编号：1662）的间接非全资附属公司。以改善生活品质及居住环境为使命， APEL 主要从事健康与环境科技创新的研究、开发及商业化。基于其多层次杀菌涂层技术（MAP-1），APEL 已在四个关键领域：飞机空气净化、水质净化、畜牧健康和环保建材，研发专门的应用配方，旨在应对全球迫切挑战。APEL 期待与全球研究人员和行业伙伴合作，推动更多健康与环境科技创新。欲知更多有关 APEL 资料，请浏览网页：https://apesl.com/传媒如有查询，请联络：AJA (IR & Communications)庾婉华电话：+852 9500 4443电邮：avy.yu@ajacapital.com.hk / info@ajacapital.com.hk Copyright 2025 亚太商讯 via SeaPRwire.com.

业绩亮点- 收入增长7.4%至15.8亿港元- 来自持续经营业务的溢利增长43.1％至3.0亿港元- 净资本负债比率由12.2％下降低至8.3％- 建议派发现金末期股息每股5.50港仙及现金特别股息每股6.00港仙- 持续通过研发及策略引进授权丰富产品线- 透过提高生产设施营运效率及杠杆，促进运营效率香港，2025年6月13日 - (亚太商讯 via SeaPRwire.com) - 从事基础药物及专科药物研发、生产、市场推广及销售的领先企业 ─ 雅各臣科研制药有限公司（「雅各臣」或「公司」；股份代号：2633.HK）今天公布公司及其附属公司（统称「集团」）截至二零二五年三月三十一日止年度（「二零二五财年」或「报告期」）的全年业绩。承接过去数年的稳健增长势头，雅各臣于本财政年度持续录得可观表现，纵使面对持续的宏观经济挑战，全年收入约为15.8亿港元，按年增长7.4%。持续经营业务的溢利飙升43.1%，达至3.0港亿元，充分体现集团坚守卓越营运及策略执行的成效。集团财务状况保持强健，为推动未来发展及股息回报提供坚实基础。在强劲业务表现及持续成本管理的支持下，集团于报告期内录得经调整EBITDA约5.7亿港元。净资本负债比率由12.2％降至二零二五财年末的8.3％，现金储备约为5.1亿港元，维持稳定水平。董事会建议派付现金末期股息每股5.50港仙（二零二四年财年：每股3.00港仙）及现金特别股息每股6.00港仙（二零二四年财年：无）。包括已派付的现金中期股息每股3.50港仙，二零二五财年的现金股息合共每股15.00港仙（二零二四财年：每股5.50港仙），按年上升172.7％。多元产品组合满足不断上升的医疗需求集团于二零二五财年的销售增长受多项因素推动。香港经历漫长的流感季节，加上多种呼吸道病原体同时活跃，带动对伤风感冒药物的需求大幅上升。人口老化，加上糖尿病及高血压等慢性疾病高发，以及精神健康需求日益增加等，进一步推升医疗需求的趋势。此外，公共卫生计划提高了公众对预防保健及早治疗的意识，增加对药物和就诊需求。在这些因素共同作用下，集团整体业务于报告期内维持销售增长。凭借丰富的基础药品及专科药物组合，集团继续具备优越的条件，满足香港不断增长的医疗需求，而透过高效的供应链，集团能够提供具成本效益的治疗选择，进一步巩固其作为香港值得信赖医疗服务供应商地位。持续推进研发与拓展专科药物组合集团于报告期内持续推进研发管线扩充，贯彻产品组合拓展战略。截至二零二五年三月三十一日，集团的研发项目包括219项处于不同开发阶段的产品。为扩大专科药物组合，集团与多家国际药厂签订授权协议，引进20项高效药物，涵盖自身免疫性疾病、肿瘤、心血管疾病、神经疾病及罕见病等多个治疗领域。这些新增药物具有出色的临床表现和市场潜力，不仅支持集团持续增长，更体现集团致力以创新疗法改善患者生活质量的承诺。以创新科技提升治疗成效集团持续扩大三氧化二砷口服液（Arsenol）的市场覆盖，该产品用于治疗急性早幼粒细胞白血病（APL），由集团与香港大学联合开发。临床试验显示，该疗法的存活率为97%，分子学缓解达100%，因而获美国食品药品监督管理局及欧洲药品管理局认定为罕见病用药。全球第三期试验将于二零二六年开始，目标是于二零二八年获上市批准。集团亦于二零二五年二月二十日达成另一重大里程碑 - 与上海复星医药（集团）股份有限公司及Fosun Kairos Biotechnology Inc. 合作，推出CAR-T疗法Axicabtagene Ciloleucel (商品名：Yikaida) 的供应链协调服务。此疗法专为治疗弥漫性大B细胞淋巴瘤而设，并已获发先进治疗产品（ATP）物流牌照，标志着集团在下一代癌症疗法领域迈出重要一步。智能生产驱动产能为配合集团提升制造能力的策略目标，集团旗下公司正美药品有限公司（Jean Marie Pharmacal Co. Limited）已于二零二五年二月于大埔创新园展开全新制药设施的建设工作。在香港政府「新型工业加速计划」的支持下，该厂房将配备十条智能生产线，用于生产无菌眼药水、固体剂型药物及口服液，通过AI、机器人及实时数据分析，提升生产效率及质量水平。试产计划预计于二零二六年底展开，重点生产专科治疗药物，针对未被满足的医疗需求。此项策略性投资不仅巩固本集团的行业领导地位，更有助推动香港发展成为先进药业制造枢纽。雅各臣主席及行政总裁岑广业先生表示：「二零二五财年对雅各臣而言是充满意义的一年，再次印证我们策略的前瞻性、团队的坚毅与投入，以及持份者对我们的信任。这些坚实基础，持续巩固我们作为香港仿制药市场领导者的地位。展望二零二六年，我们对业务前景充满信心。随着医疗政策改革推进，以及人口老化与慢性病带动药物需求上升，将持续推动基础药物市场增长。凭借强大的产品线、不断拓展的合作伙伴关系，以及数码创新，我们已具备有利优势，把握增长机遇，为集团业务创造可持续价值。」关于雅各臣科研制药有限公司（股份代号：2633）雅各臣是本地领先的医药公司，拥有垂直整合的业务，包括基础药物及专科药物的研发、生产、分销、销售及物流。作为本地主要的非专利药供货商，集团在香港私营及公营领域，具有最广泛的销售及分销的市场覆盖，并积极向策略性选择的亚洲市场伸延扩展。集团于香港设有9间PIC/S GMP认证的非专利药生产设施，并在各种治疗药物类别中拥有广泛的产品组合与享有优越市场地位。同时，集团一直致力透过增加各种高增值产品，策略性地扩大其非专利药的产品组合。扎根香港，集团已于中国、澳门、台湾及柬埔寨开设营运子公司，建立区域性商业平台，以把握亚太区及大中华地区的市场潜力。而自 2017 年 6月 1 日，集团获纳入 MSCI 香港微型股指数成份股。更多详情请浏览臣科研制药有限公司网站： http://www.jacobsonpharma.com Copyright 2025 亚太商讯 via SeaPRwire.com.

- 「创业快綫」终极决选10间优胜初创顺利诞生，绿创能源有限公司夺得「环境、社会、企业管治大奖」，安神生物科技有限公司夺得「我最喜爱初创大奖」- 「创业快綫」终极决选日邀请到逾200名业界人士参与，助初创建立人脉及增加曝光，持续推动本港创业生态圈发展- 本届优胜初创业务主要集中于健康科技，亦有多间来自绿色科技、智慧城市及人工智能等领域香港，2025年6月13日 - (亚太商讯 via SeaPRwire.com) - 香港贸易发展局（香港贸发局）举办的第八届初创培育计划「创业快綫」终极决选顺利完成，10间优胜初创诞生。大会今年继续设有「环境、社会、企业管治大奖」(ESG Award)，表扬最具可持续发展及社会效益的初创企业，最终由绿创能源有限公司嬴得此奖项。至于现场观众一人一票选出的「我最喜爱初创大奖」，则由安神生物科技有限公司夺得。10间优胜初创将可参与一系列由贸发局组织的本地及海外的商贸活动，全面建人脉、拓市场、增曝光、觅伙伴。贸发局全力支援及推动初创企业发展，协助他们进军海外及内地市场，推广香港创科优势。香港贸发局商品贸易及创新总监兼对外事务总监黄燕表示： 「『创业快綫』作为香港贸发局的旗舰初创培育计划，一直推动本港最具潜力及创新的科技初创茁壮成长，致力协助本地初创提升实力及建立人脉，开拓新市场同时寻找商业及融资伙伴，并提升品牌知名度。自2018启动计划以来，我们已协助70间本地初创提升规模，同时扩展业务至海外市场，不少已取得卓越成就及赢得国际奖项，得到重大投资及建立重要的商业伙伴关系，充份体现这个平台加速推动香港初创成功发展。」第八届「创业快綫」报名公司超过200间，反应踊跃。十间优胜初创业务主要集中于健康科技，亦有多间来自绿色科技、智慧城市及人工智能等领域。今年「创业快綫」终极决选日吸引逾200位业界人士参与，包括一众投资者及商界领袖，现场亦设有初创展览，由「创业快綫」入围初创向与会人士进行业务介绍。贸发局将为优胜初创提供多元化商贸交流及配对活动晋身「创业快綫」最后20强的初创，在今天的终极决选上简介业务及创业理念，在现场接受评判的即场提问及评分，最终胜出的10间优胜初创分别为：ACTuWISE Limited、Decennium Platforms Limited、安神生物科技有限公司、Digitoe Limited、世美拉有限公司、汤宏健康科技有限公司、Firefilm Group Limited、艾柏轮科技有限公司、Entoptica Limited及绿创能源有限公司。（请按此下载完整得奖名单及初创简介）香港贸发局将为优胜初创安排一系列的交流考察及推广活动，与潜在投资者、买家和合作伙伴会面。评判赞赏优胜初创紧贴市场发展及决选表现评判之一阿里云(亚太北区)资深顾问车品觉表示：「每届新入选的初创都给我们带来惊喜，面对AI迅速发展，不少企业都迅速将AI融入实体业务，可见本地初创人才紧贴市场趋势，同时具备创新思维及一定实力。」另一评判香港初创企业协会主席杜伟樑亦表示：「本届参赛初创质素颇高，提供的产品及服务牵涉不同科技领域，特别是在人工智能、绿色科技和医疗创新等方面。我们乐见新一代初创在创新及科技各范畴都持续推陈出新，为社会整体发展出一份力，展现出无限潜力和创造力。香港初创持续蓬勃增长，去年香港初创企业已达4,694间再创新高，显示香港的营商吸引力有增无减，继续是设立初创的理想地点，前景亮丽，相信今年的优胜初创将可透过『创业快綫』获得更多拓展市场及建立人脉的宝贵发展机会。」「创业快綫」助初创取得公司投资及合作机会「创业快綫」为初创提供全面的宣传机会，优胜初创企业将可亲身参与内地及海外的展览会，以及与本地及世界各地的投资者会面接洽等，从而了解更多行业动态、海外市场趋势及投资者取向，以建立商脉和拓展市场及业务。上届优胜初创之一途龄科技(Libpet Tech)最近更完成了300万美元的种子轮融资，筹集所得资金将用于技术升级及拓展国际市场。途龄科技行政总裁徐华峰表示：「参加『创业快綫』成功为公司增加曝光及提升品牌知名度，获得不少潜在客户及投资者关注，在此十分感谢投资者对公司的信心。公司将携手公私营合作伙伴，将机器人技术融入日常生活，推动以人为本的智慧出行。」第四届「创业快綫：国际篇」12月举行 全球初创大比拼香港贸发局一直致力加强本地与海外创业生态圈的交流，巩固香港致力作为亚洲创科枢纽的竞争优势。于2022年首度举行的「创业快綫：国际篇」，过去三届吸引环球各地如澳洲、法国、德国、日本、韩国、土耳其、新加坡、阿联酋及美国等地的初创报名。第四届「创业快綫：国际篇」今年将继续在12月初的「创业日」举行，协助胜出的海外初创落户香港，并透过香港的平台探索大湾区及其他内地市场。「创业快綫」网页：https://portal.hktdc.com/startupexpress/tc/图片下载：http://bit.ly/4jPwedc10间「创业快綫」优胜初创企业顺利诞生，得奖初创代表与评判及嘉宾一起合照。后排由左至右为：阿里云（亚太北区）资深顾问车品觉、兴迅集团主席兼董事总经理张益麟、道源资本集团首席执行官陈甄灏、香港贸发局商品贸易及创新总监兼对外事务总监黄燕、Betatron Venture Group管理合伙人兼执行长Matthias Knobloch、PRD初创投资主席汤雷、香港初创企业协会主席杜伟樑。「创业快綫」终极决选请来中小学生到场展示不同科创方案，由2023年优胜初创 Big Bang Academy 联合创办人唐蒨怡提供指导及颁发奖状。「创业快綫」终极决选邀请逾200名业界人士参与，让初创与投资者和商界领袖等一起交流。「创业快綫」终极决选现场设有初创展览，入围初创为与会者介绍公司业务。香港贸发局新闻中心：http://mediaroom.hktdc.com/tc传媒查询新闻界如有查询，请联络香港贸发局传讯及公共事务部：苏显博 电话：(852) 2584 4049 电邮：stanley.hp.so@hktdc.org黄家欣 电话：(852) 2584 4524 电邮：katy.ky.wong@hktdc.org张希汶 电话：(852) 2584 4272 电邮：serena.hm.cheung@hktdc.org刘茸 电话：(852) 2584 4472 电邮：clayton.y.lauw@hktdc.org香港贸易发展局简介香港贸易发展局(香港贸发局)是于1966年成立的法定机构，负责促进、协助和发展香港贸易。香港贸发局在世界各地设有超过50个办事处，其中13个设于中国内地，致力推广本港作为双向环球投资及商业枢纽。 香港贸发局通过举办国际展览会、会议及商贸考察团，为企业(尤其是中小企)开拓内地和环球市场的机遇。香港贸发局亦通过研究报告和数码资讯平台，提供最新的市场分析和产品资讯。有关香港贸发局的其他资讯，请浏览www.hktdc.com/aboutus/tc。 Copyright 2025 亚太商讯 via SeaPRwire.com.

With the Department of Labour Peninsular Malaysia’s approval, the Ria Payroll Management System, coupled with the Ria Wallet and Prepaid Card Program, in collaboration with Mastercard, aims to promote financial inclusion among unbanked migrant workers throughout Malaysia, offering employers a secure and compliant way to manage their payroll needs.KUALA LUMPUR, June 13, 2025 - (ACN Newswire via SeaPRwire.com) - Ria Money Transfer (“Ria”), a global leader in the cross-border money transfer industry and business segment of Euronet Worldwide, Inc. (NASDAQ: EEFT) has been officially approved by the Department of Labour Peninsular Malaysia (JTKSM) for the disbursement of digital wage payments via the Ria Wallet. By streamlining wage distribution through digital means, the Ria Prepaid Card Program, in collaboration with Mastercard, provides an omni-channel solution to employers who may struggle with conventional banking access for their workforce.The Ria Wallet facilitates various financial activities such as depositing funds, withdrawing cash from ATMs, paying bills, and conducting domestic and international transfers. Customers will also be able to make payments in millions of locations in Malaysia via QR payment linked to DuitNow. In addition, the Ria Wallet streamlines payroll management for Malaysia-based companies throughout industries heavily dependent on migrant workers, including construction, agriculture, and manufacturing.According to the International Organization of Migration (“IOM”), migrants represent an estimated 15.3% of Malaysia’s total workforce, many of whom are unbanked. The Ria Wallet addresses the challenges faced by both workers and employers in the country's cash-centric payment landscape.Ria’s presence in Malaysia since 2001 has positioned Ria as one of the leading players in the money transfer industry. Leveraging its strong physical network of 624,000 locations worldwide and its presence in nearly 200 countries and territories, Ria aims to provide a diverse and seamless service experience to all customers.Espen Kristensen, Ria Money Transfer’s Managing Director Asia Pacific, expressed his excitement for the expansion of Ria's service portfolio in Malaysia. He emphasized, “We understand the challenges employers in Malaysia face when it comes to managing wages for their workers. Through the Ria Wallet, companies will be able to benefit from a digital solution that improves transparency and compliance across their operations”.In collaboration with Mastercard, The Ria Prepaid Card Program underscores the company’s commitment to driving positive social impact through the financial empowerment of different communities worldwide. About Ria Money TransferRia Money Transfer, a business segment of Euronet (NASDAQ: EEFT), delivers innovative financial services including fast, secure, and affordable global money transfers. With the world’s largest cross border real-time money movement network, Ria moves money where it matters. Bridging the gap between digital and physical spaces, Ria’s omnichannel products and services provide unprecedented consumer choice, including real-time payments, mobile wallets, currency exchange, home delivery, and cardless ATM payouts. Ria’s global infrastructure, powered by the Dandelion real-time, cross-border payments network, facilitates financial access to customers, agents and partners alike. By creating new market opportunities and promoting economic growth around the world, Ria opens ways for a better everyday life. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE / INDIA, June 13, 2025 - (ACN Newswire via SeaPRwire.com) - Asia Research & Engagement (ARE), a leading sustainability-focused consultancy and capital markets engagement firm, has expanded its India team with two senior appointments: Shishir Soti, Director, Global Operations and Partnerships and Arun Kumar, Strategic Advisor – Power Markets and Technology Innovation.Founded in 2013 and headquartered in Singapore, ARE works across Asia’s key economies – including China, India, and Japan – to drive sustainability outcomes through the alignment of capital markets, corporate strategy, and policy. India’s expanding influence in energy, agriculture, and capital markets makes it not just a domestic focus but a regional anchor for accelerating Asia’s net-zero transition.“India is already making bold strides on its decarbonisation journey,” said Benjamin McCarron, Founder & Managing Director, ARE. “Expanding our footprint here strengthens our ability to connect investor expectations and corporate ambition across the region, from Tokyo to Bangkok to Singapore. India’s scale and innovation are pivotal to designing future-fit systems across all of Asia.”Shishir Soti brings more than 25 years of experience to ARE, having held senior positions in banking and financial services at institutions including Standard Chartered and ICICI Bank, as well as senior roles at environmental groups such as the Shakti Sustainable Energy Foundation and Environmental Defense Fund. At ARE he will help deepen the integration of India into ARE’s regional programmes on financed emissions, sustainable food systems, and transition financing. He will also spearhead stakeholder engagement and fundraising strategy for ARE’s India programmes, advancing efforts to align Indian corporates and banks with net-zero goals.“India’s ambition to reach net-zero by 2070 has implications far beyond its borders,” said Soti. “Its energy and agricultural transitions will shape supply chains, investment flows, and climate ambition throughout Asia. I’m proud to support ARE’s work connecting policy, capital, and corporate action at this critical intersection.”Arun Kumar joins ARE with more than 25 years of experience in power markets, technology, and strategy, having held leadership positions at PTC India, HSBC Securities, KPMG and CRISIL where he was consistently ranked among India’s top energy analysts. He will provide strategic insights into regulatory trends, market innovation, and grid decarbonisation.“ARE’s investor-informed approach has already helped shift conversations in China, Japan, and Southeast Asia,” said Kumar. “India’s power market is on the cusp of transformation, and I look forward to helping shape the trajectory through collaborative engagement and technology foresight.”Soti and Kumar will work closely with Rituj Sahu, Director – Protein Transition (India), who has been leading ARE’s work on food systems, climate finance, and impact stewardship in India since 2022. Their collective expertise positions ARE to deepen its regional impact across three core pillars: Energy transition and financed emissions engagement with corporates and banks; Sustainable food and agriculture systems, with a focus on the protein transition; Capital mobilisation, bridging global finance with local sustainability outcomes.The India expansion complements and strengthens ARE’s ongoing work in Singapore, China, Taiwan, Japan, and Thailand – creating a more connected and coordinated platform for sustainable transformation across Asia.“To solve regional sustainability challenges, we need local intelligence, regional coordination, and global capital alignment,” added McCarron. “India is integral to the systems change ARE is driving across the region.”About Asia Research & Engagement (ARE)Creating change through investor-backed engagement. ARE's pioneering approach fills an engagement gap to bring leading investors into dialogue with Asian-listed companies. ARE currently works with investors representing US$10trillion. ARE covers Asian-listed companies from the financial sector, energy-related industries, and food value chains, seeking to advance a sustainable and compassionate Asia.For media interviews and further enquiries, please contactWani DiwakarAsia Research & Engagement (ARE) wani.diwarkar@asiareengage.com Copyright 2025 ACN Newswire via SeaPRwire.com.

KEY HIGHLIGHTS- Revenue up by 20.7% to HK$782.3 million- Gross profit increased by 22.4% to HK$413.7 million- Consolidated profit attributable to equity shareholders grew by 51.2% to HK$197.3 million- The Board recommends a final dividend of HK11.5 cents per share- Flagship proprietary brands Ho Chai Kung, Po Chai Pills, and Flying Eagle Woodlok Oil delivered robust growth through effective brand management campaigns- Concentrated Chinese medicine granules (“CCMG”) remained resilient, providing a steady contribution to overall business performanceHONG KONG, Jun 12, 2025 - (ACN Newswire via SeaPRwire.com) - JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the "Group"), a leading branded healthcare products marketer and distributor in Hong Kong, today announced the annual results of the Group for the year ended 31 March 2025 ("FY2025" or the "Reporting Period").Despite a lackluster retail environment in Hong Kong, JBM Healthcare delivered a robust financial and operational performance in FY2025. Revenue from the branded healthcare business rose by 20.7% year-on-year to HK$782.3 million. Gross profit grew by 22.4% to HK$413.7 million, while consolidated profit attributable to equity shareholders surged 51.2% to HK$197.3 million.This significant increase in consolidated profit attributable to equity shareholders was driven by robust sales of flagship brands - including Ho Chai Kung, Po Chai pills, and Flying Eagle Woodlok Oil, complemented by the resilient performance of its CCMG business. These strong results underscore the effective execution of the Group’s integrated sales and marketing strategies, and its strategic foresight in capturing growth opportunities in the branded consumer healthcare market across Hong Kong, Macau, and major cities in the Greater Bay Area.The Board recommends a final dividend of HK11.5 cents per share. Including the interim dividend of HK5.5 cents per share already paid, the total dividend for FY2025 will be HK17.0 cents per share.Solid Performance Across Core SegmentsIn the branded medicines business, sales revenue recorded strong growth of 43.2%, propelled by Ho Chai Kung’s sustained market momentum. Ho Chai Kung successfully expanded its market penetration through precisely targeted marketing initiatives that broadened its consumer base while simultaneously reinforcing brand recognition.Sales in the proprietary Chinese medicines segment grew by 5.0% against the backdrop of softened local retail sentiment of Chinese medicines and herbs, driven by the momentum of flagship brands Po Chai Pills and Flying Eagle Woodlok Oil, alongside the resilient performance of the CCMG business. Po Chai Pills enhanced brand visibility through sustained TVC placements and title sponsorship of popular television programs. Meanwhile, Flying Eagle Woodlok Oil reinforced its market position with an integrated campaign themed “Flying Eagle – The Real Master’s Choice”, highlighted by a viral “Flying Eagle Bro” billboard at Tsim Sha Tsui Star Ferry Pier, which tripled brand awareness.In the health and wellness products segment, revenue increased by 44.9%, driven by the steady growth of Oncotype DX Breast Recurrence Score Test (“Oncotype DX”), along with the expansion of our product portfolio and enhanced marketing efforts to meet consumer healthcare demands of the mass market. Oncotype DX has gained increasing recognition among healthcare professionals in Hong Kong and Macau.Capturing the Growth Potential of Cross-Border E-Commerce and TCM SectorThe Group has made steady progress in expanding its online presence on cross-border e-commerce platforms as well as strategically positioned to capitalise on the growing traditional Chinese medicine (“TCM”) sector in Hong Kong and the Greater Bay Area. The Group’s flagship stores on Tmall Global and JD.com have performed strongly, with Ho Chai Kung ranking among the top 10 overseas medicines during the 2024 Double 11 sales event. To drive sustainable growth, the Group is also diversifying into new categories while enhancing both its B2B and B2C sales networks.Strategic Acquisition of Tin Hee TongIn April 2025, the Group completed the acquisition of a 90% stake in Tin Hee Tong Medicine Factory, Limited, whose flagship product, Tin Hee Tong Tin Hee Pills, is a well-recognised brand in Hong Kong and mainland China, particularly among female consumers for its efficacy in regulating the menstrual cycle and supporting reproductive health. The acquisition expands the Group’s proprietary Chinese medicine portfolio and creates synergies by integrating Tin Hee Tong’s brand with the Group’s manufacturing and marketing strengths. Leveraging its expertise in brand management, the Group will launch a comprehensive marketing campaign to boost awareness, enhance engagement, and broaden distribution.Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, commented, “Amid the challenging retail environment, we delivered strong financial and operational performance, driven by our robust portfolio, the enduring appeal of our flagship brands, and our unwavering focus on operational excellence.”“Looking ahead, we remain committed to disciplined growth and operational excellence. With rising health awareness, increasingly sedentary lifestyles, and an ageing population continuing to fuel demand, we are well-positioned to capitalise on growth opportunities in the consumer healthcare sector. We will continue to sharpen our brand management capabilities, strengthen our core brand equity, expand our product offerings, and extend our market reach.”About JBM (Healthcare) Limited (Stock Code: 2161)JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and other select countries. The Group is a distinctive player in the sector with marketing expertise and heritage in pharmaceuticals that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Tin Hee Tong Tin Hee Pills, Flying Eagle Woodlok Oil), Tong Tai Chung Woodlok Oil, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.